What Cinitapride treats: main uses and benefits

Cinitapride is used in situations involving certain distressing symptoms related to upper gastrointestinal function and provides supportive relief when symptoms interfere with routine activities. It is applied across domains where additional symptomatic support is needed and contributes to easing the overall symptom load during periods of heightened symptoms.

The medicine is relevant in conditions involving episodic or fluctuating manifestations, such as Gastroesophageal Reflux Disease (GERD) and functional dyspepsia. It assists with managing symptoms related to physical discomfort, including heartburn, acid regurgitation, postprandial fullness, bloating, and sickness.

It is indicated to treat gastrointestinal disorders such as symptomatic dyspepsia and gastro-oesophageal reflux. It supports the patient during difficult episodes by easing discomfort and is helpful in situations requiring additional symptomatic assistance.

---

Quick Fact: Role in Managing Heartburn & Fullness Symptoms

Cinitapride is considered relevant for easing challenging symptoms that create noticeable functional strain, helping to manage symptom clusters that may become intense or disruptive.

Cinitapride is restricted to the adult population and is contraindicated in several specific groups and medical conditions, as defined in official regulatory labeling.

Who Must Not Use Cinitapride (Contraindications)

Use of Cinitapride is prohibited for patients with:

• Hypersensitivity (allergy) to cinitapride or any related ingredients.
• Proven neuroleptic-induced tardive dyskinesia (a neurological movement disorder).
• Gastrointestinal trauma where stimulating motility may be harmful, specifically: gastrointestinal bleeding, mechanical bowel obstruction, or gastrointestinal perforation.

Populations Requiring Caution or Exclusion

Population Group	Regulatory Status
Pediatric Population (Children/Adolescents)	Not advisable or Use not established due to a lack of safety and efficacy data.
Pregnancy	Not recommended or Contraindicated as a precautionary measure due to insufficient human safety data.
Lactation/Breastfeeding	Not recommended as a precautionary measure, as it is unknown if the substance passes into human milk.
Elderly Patients (Geriatric)	Use requires caution due to an increased risk of side effects, such as tardive dyskinesia.
Hepatic or Renal Impairment	Use requires caution and may necessitate monitoring.

Interaction Map: Interactions with other medicines and products — official regulatory information for Cinitapride

Interaction scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	CYP3A4 Inhibitors (e.g., Macrolide antibiotics, HIV protease inhibitors), Antidopaminergic drugs, CNS depressants, Anticholinergic drugs, Opioid Analgesics.
Specific interacting medicines (if explicitly listed)	Ketoconazole, Indinavir, Ritonavir, Erythromycin, Clarithromycin, Troleandomycin, Nefazodone, Digoxin.
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic Interaction (Metabolism): Cinitapride is metabolized by CYP3A4 and CYP2C8. Pharmacokinetic Interaction (Absorption): Prokinetic effect may reduce the absorption of co-administered drugs. Pharmacodynamic Interaction: Results in additive sedative effects and antagonistic gastrointestinal effects.
Timing-based interaction rules (if applicable)	No specific mandatory timing or administration separation rules are documented.
Population-specific interaction notes (if applicable)	No explicit statement links an increased risk or severity of a specific interaction to populations with hepatic or renal impairment in the regulatory interaction summary.
Interaction-related restrictions	Co-administration with Alcohol enhances sedative effects. Combination with potent CYP3A4 inhibitors may lead to increased Cinitapride exposure. Combination with Anticholinergics or Opioid Analgesics will reduce the intended prokinetic effect of Cinitapride.

---

Interaction classifications (high-level)

Classification	Official Regulatory Statement
Interaction severity classification (as defined in official documents)	Contraindicated Combinations: None explicitly stated due to interaction risk. Clinically Significant: Combinations with potent CYP3A4 inhibitors (risk of increased exposure) and co-administration with CNS depressants/alcohol (risk of enhanced sedation).
Regulatory basis (EMA / FDA / etc.)	Based on official Summary of Product Characteristics (SmPC) and equivalent government-approved prescribing information.
Interaction-context constraints (as defined in official documents)	Interactions are defined by the consequences of metabolic clearance alteration, pharmacodynamic potentiation, pharmacodynamic antagonism, and reduced absorption of co-administered medicines.

---

Resulting interaction structure

Official interaction statements:

• Co-administration with potent CYP3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics, HIV protease inhibitors) may alter Cinitapride clearance and has been shown to increase Cinitapride plasma exposure (AUC) approximately twofold.
• The drug is primarily metabolized by the CYP3A4 enzyme system and, to a lesser extent, by CYP2C8.
• Cinitapride enhances the sedative effects of alcohol, tranquillisers, hypnotics, and narcotics.
• Cinitapride's prokinetic effects may be reduced by atropinic anticholinergics and opioid analgesics.
• The gastroprokinetic action of the drug may reduce the absorption and effect of Digoxin.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents define Cinitapride's interaction profile around two primary themes: metabolic susceptibility via the CYP3A4 enzyme system, which increases its exposure when co-administered with inhibitors, and pharmacodynamic effects, which results in the potentiation of other CNS depressants and the antagonism of its own gastrointestinal action by anticholinergic and opioid drugs. The official documentation also explicitly notes that the prokinetic effect of Cinitapride can reduce the absorption of co-administered medicines such as Digoxin.

Cinitapride functions primarily as a dual-action prokinetic agent by interacting with specific neurotransmitter receptors in the gastrointestinal tract. Its mechanism involves agonist activity at 5-hydroxytryptamine type 4 (5 -HT4) receptors and antagonist activity at dopamine type 2 (D2) receptors.

Activation of 5 -HT4 receptors on enteric neurons leads to the release of acetylcholine (A Ch). Acetylcholine is the principal excitatory neurotransmitter in the enteric nervous system, and its increased release enhances cholinergic signaling within the myenteric plexus. Simultaneously, the blockade of D2 receptors removes the inhibitory dopaminergic influence on acetylcholine release. This combined activity results in the potentiation of cholinergic neurotransmission. The resulting increased cellular signaling directly modulates smooth muscle contraction and propagation velocity, leading to an overall enhancement of gastrointestinal motility, including increased tone and coordinated peristaltic movement.

Cinitapride is administered through specific routes and follows a defined dosing schedule. The medicine is most commonly prescribed as a 1 mg tablet intended for oral administration. A sterile solution for intramuscular use is also a documented route in certain clinical settings.

The standard oral dosing regimen for adults over 20 years of age is 1 mg taken three times a day. This regimen establishes a total daily dose of 3 mg. The established guidance advises against increasing this total daily intake.

A critical element of its use is the timing of administration. The tablet must be taken 15 minutes before each of the three main meals. This specific time-relationship is a key instruction for the proper administration of the medicine. Regarding specific populations, the standard regimen applies to adults, and the medicine's use is not advisable for children and adolescents because of limited data and experience in these age groups.

---

Research Evidence / Overview of Studies for Cinitapride

Evidence for Cinitapride's Use in Treating Functional Dyspepsia

Research explored Cinitapride in studies involving conditions related to functional dyspepsia, a condition marked by functional limitations and chronic, unexplained upper digestive discomfort. Studies conducted for this purpose have primarily involved controlled trials, where Cinitapride was evaluated in controlled trials that included comparisons against inactive substances or other interventions. The main focus of these studies was on outcomes related to physical discomfort such as feeling full quickly, bloating, or pain in the upper abdomen. The findings describe patterns observed in the studies where research highlights changes measured during the study period related to patient-reported outcomes describing perceived discomfort. However, the evidence quality varies across studies, and the findings were mixed regarding the consistency of the results across all studies.

Evidence for Cinitapride's Use in Treating Gastroesophageal Reflux Disease (GERD)

Cinitapride was also evaluated in research settings focused on conditions related to Gastroesophageal Reflux Disease (GERD), a condition involving periods of heightened symptoms of heartburn and acid regurgitation. This research explored outcomes describing episodic or acute changes in patient-reported outcomes related to acid flowing back from the stomach. Studies in this area were relevant in trials assessing short-term or episodic symptom patterns, and some data show patterns related to changes measured in the study population. Comparative evidence is lacking against a full spectrum of other treatments, and findings often reflect a limited follow-up duration. While the research provides insight into short-term changes, more robust and consistent data are still emerging.

Long-term Studies and Follow-up

Research regarding the long-term use of Cinitapride is ongoing, but long-term effects are not fully established. Most clinical trials studied responses over defined time intervals that only capture short-term changes, meaning that follow-up durations were limited. There is limited information for long-term outcomes, including the durability of any outcomes related to perceived discomfort.

Evidence in Special Populations

Cinitapride was evaluated in studies involving adults, but data for certain groups remain insufficient. Specifically, subgroup findings are uncertain or non-existent for several populations who might experience conditions where symptoms may vary in intensity. Research applies only to the populations studied, meaning the applicability of these findings to special populations is generally not established.

What Is Still Uncertain About Cinitapride

The overall evidence landscape for Cinitapride contains several gaps and areas of uncertainty. Long-term effects are not fully established, and comparative evidence is lacking. Certainty remains low in some areas because sample sizes were modest in various trials. Overall, research is needed to further investigate patient-reported outcomes describing perceived discomfort and to better understand all the observed patterns.

Key Studies & References

1. Ficha técnica / Resumen de las Características del Producto (Summary of Product Characteristics) - Cinitapride (AEMPS)

Storage and Disposal Requirements for Cinitapride

The storage and disposal instructions for Cinitapride tablets are based strictly on regulatory requirements to ensure product integrity and safe handling.

Official Storage Conditions

Cinitapride tablets do not require any special storage temperature conditions. The medicine must be kept in its original packaging and protected from excessive heat and moisture. The officially labeled shelf life for the product is typically 5 years when stored under these specified conditions. As with all medications, Cinitapride must be stored safely, out of the sight and reach of children.

Product Disposal

Regulatory documents state there are no special requirements for disposal of Cinitapride, but any unused or expired product must be disposed of in accordance with local requirements. General guidance recommends mixing unwanted medicine with an undesirable substance before disposal in household trash, rather than flushing or pouring down a sink.